Clinical Trial

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Trial Details
NCT Number NCT07165847
Lead Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy, Neoadjuvant Chemoimmunotherapy
Enrollment 40 participants
Start Date 2025-07-23
Primary Completion 2028-09-23 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-10